Small bowel adenocarcinoma: An overview.

Area of Science:

• Gastroenterology
• Oncology

Background:

• Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with a poor prognosis.
• Delayed diagnosis due to vague symptoms and imaging challenges negatively impacts patient outcomes.
• Current management relies on extrapolated data from other gastrointestinal cancers due to a lack of specific guidelines.

Purpose of the Study:

• To highlight the diagnostic challenges and prognostic factors associated with small bowel adenocarcinoma.
• To review current treatment approaches and identify gaps in management guidelines.
• To emphasize the need for further research into SBA pathogenesis and novel therapeutic strategies.

Main Methods:

• Review of recent advances in diagnostic imaging, including multidetector computed tomography, magnetic resonance imaging, and capsule endoscopy.
• Analysis of current treatment modalities, primarily surgery followed by adjuvant therapy.
• Synthesis of existing literature comparing SBA prognosis with colorectal and gastric carcinomas.

Main Results:

• Advanced imaging techniques facilitate earlier and more accurate diagnosis of SBA.
• Surgery remains the primary treatment, but adjuvant therapy protocols are not standardized.
• SBA prognosis is intermediate, worse than colorectal cancer but better than gastric cancer.

Conclusions:

• Despite diagnostic improvements, SBA management lacks specific guidelines, hindering optimal patient care.
• Further research into molecular characteristics and pathogenesis is crucial for developing targeted therapies.
• International collaboration is essential to gather sufficient data for robust clinical trials and improved outcomes in rare SBA cases.